Preparation of injectable hydrophilic dextran/AgNPs nanocomposite product: White light active biomolecules as an antitumor agent

Incidence of various cancers including melanoma continues to rise worldwide. While treatment options have expanded in the recent years, the benefit of these treatments suffer from short period of duration for many patients. Hence, new treatment options are highly desired. Here, we propose a method c...

Full description

Saved in:

Bibliographic Details
Published in:	International journal of biological macromolecules Vol. 245; p. 125215
Main Authors:	Bunyatova, Ulviye, Hammouda, Manel Ben, Y.Zhang, Jennifer
Format:	Journal Article
Language:	English
Published:	Netherlands Elsevier B.V 01-08-2023
Subjects:	Anti-Bacterial Agents - chemistry Antineoplastic Agents - pharmacology Antitumor efficiency Dextran Dextrans Humans Light Melanoma cells Metal Nanoparticles - chemistry Nanocomposites Plasma substitute polysaccharides Silver nanoparticles Dextran Antitumor efficiency Plasma substitute polysaccharides Melanoma cells Silver nanoparticles
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Incidence of various cancers including melanoma continues to rise worldwide. While treatment options have expanded in the recent years, the benefit of these treatments suffer from short period of duration for many patients. Hence, new treatment options are highly desired. Here, we propose a method combining a Dextran/reactive-copolymer/AgNPs nanocomposite and a harmless visible light approach to obtain a plasma substitute carbohydrate-based nanoproduct (D@AgNP) that shows strong antitumor activity. Light-driven polysaccharide-based nanocomposite provided essential conditions for extra small (8-12nm) AgNPs capping with subsequent specific self-assembly into spherical-like cloud nanostructures. Obtained biocompatible D@AgNP are stable over six months at room temperature and demonstrated absorbance peak at 406 nm. New formulated nanoproduct revealed efficient anticancer properties against A375 with IC50 0.0035 mg/mL following 24-h incubation; complete cell death is achieved at 0.001 mg/mL and 0.0005 mg/mL by 24- and 48-h time points, respectively. SEM examination shows that D@AgNP altered the shape of the cell structure and damaged the cell membrane. TEM finding shows that D@AgNP are mostly localized at vesicles such as the endosomes, lysosomes and mitochondria. It is anticipated that the introduced new method serves as the cornerstone for improving the generation of biocompatible hydrophilic carbohydrate-based anticancer drugs.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 U.B. conceived of the presented idea, synthesized functional D@AgNP, performed and examined their characterization and wrote the manuscript J.Z. supervised the cytotoxicity studies and edited the manuscript. All authors read and approved the manuscript. All authors discussed the results and commented on the manuscript. Author Contributions M.B. prepared and treated A375 cells, performed the in-vitro cytotoxicity studies and generated statistical analyses of antitumor studies and edited the manuscript.
ISSN:	0141-8130 1879-0003
DOI:	10.1016/j.ijbiomac.2023.125215